-
Sumitomo Dainippon Partners with Profex to Promote Antipsychotics in China
•
Japan-based Sumitomo Dainippon Pharma Co., Ltd has announced a partnership with Profex, a trade company in Shanghai. The collaboration aims to promote Lonasen (blonanserin) and Latuda (lurasidone), both antipsychotic medications, in the Chinese market. Financial details of the partnership were not disclosed. Epidemiological ContextAccording to the latest epidemiological survey in…
-
Eli Lilly Partners with AmoyDx and Burning Rock for Retevmo Companion Diagnostics
•
The 5th China International Import Expo (CIIE) saw US-based Eli Lilly (NYSE: LLY) announce a partnership with China-based Amoy Diagnostics Co., Ltd (AmoyDx) and Burning Rock Biotech Ltd (NASDAQ: BNR). The collaboration aims to enhance the development of companion diagnostics (CDx) for Retevmo (selpercatinib), the world’s first highly-selective RET kinase…
-
BioNTech’s Comirnaty Gets Limited Authorization in China Amid Scholz Visit
•
Germany-based mRNA specialist BioNTech (NASDAQ: BNTX) reportedly benefited from German Chancellor Olaf Scholz’s visit to China this week. Chinese authorities agreed to a limited authorization for the mRNA-based COVID-19 vaccine Comirnaty (BNT162b2) to be used by German national expatriates living in China, according to media sources including Bloomberg, quoting Scholz.…
-
Organon’s Q3 Results Show Women’s Health Segment Outperforms Amid Global Revenue Decline
•
US-based Organon & Co. (NYSE: OGN), a firm with a strong focus on women’s health that split from Merck, Sharp & Dohme (MSD, NYSE: MRK) in mid-2021, released its Q3 2022 financial results. Total global revenues were down 4% year-on-year (YOY) in real terms to USD 1.537 billion, but up…
-
Organon Signs MOU with China’s National Health Commission at CIIE
•
Organon & Co. (NYSE: OGN), a firm with a strong focus on women’s health that split from Merck, Sharp & Dohme (MSD, NYSE: MRK) in mid-2021, announced at the 5th China International Import Expo (CIIE) the signing of a memorandum of understanding (MOU) with the National Health Commission (NHC). The…
-
Ascletis Pharma Presents Phase I Study Results for ASC43F at AASLD
•
China-based Ascletis Pharma Inc. (HKG: 1672) made a poster presentation detailing the abstract of a Phase I study for ASC43F in a single dose to treat non-alcoholic steatohepatitis (NASH) at The Liver Meeting 2022 of the American Association for the Study of Liver Diseases (AASLD). The presentation highlighted the drug’s…
-
Ji Xing Pharmaceuticals’ Omecamtiv Mecarbil Accepted for Review by CDE
•
Shanghai-based Ji Xing Pharmaceuticals, backed by RTW Investments, announced that a market filing for its investigational omecamtiv mecarbil has been accepted for review by the Center for Drug Evaluation (CDE). The small molecule is a potential first-in-class cardiac myosin activator being developed as a treatment for heart failure with reduced…
-
Sophway Raises ‘Tens of Millions’ in Angel Round for Endoscope Development
•
Sophway Technology, a full HD endoscope system developer based in Shenzhen, has reportedly raised “tens of millions” of renminbi in an angel financing round. The round was led by Bioching Capital, with contributions from Vinno Capital and TusStar. The proceeds will be used to advance the domestic development of endoscope…
